Catalyst
Slingshot members are tracking this event:
Novo Nordisk's (NVO) Fiasp (Fast-Acting Insulin Aspart) in Type 1 and Type 2 Diabetes Granted Positive Opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 14, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fiasp, Fast-acting Insulin Aspart, Type 1 Diabetes, Type 2 Diabetes, Positive Opinion, European Medicines Agency, Chmp
